In-vivo CRO 시장 보고서 : 유형별, GLP 유형별, 적응증별, 지역별(2024-2032년)

The global in-vivo CRO market size reached US$ 4.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.12% during 2024-2032.

In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services. As compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations. As a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.

In-vivo CRO Market Trends:

The increasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth. Additionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors. Furthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth. Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vivo CRO market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, GLP type and indication.

Breakup by Type:

Rodent

Rats

Mice

Others

Non-Rodent

Breakup by GLP Type:

Non-GLP

In House

Outsourcing

GLP Toxicology

In House

Outsourcing

Breakup by Indication:

Autoimmune/Inflammation Conditions

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumor

Others

CNS Conditions

Epilepsy

Parkinson's Disease

Huntington's Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Diabetes

Obesity

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories International Inc., Evotec SE, ICON plc, Iris Pharma (Abionyx Pharma), Labcorp Drug Development (Laboratory Corporation of America Holdings), North American Science Associates LLC, Parexel International Corporation, Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), Pronexus Analytical AB, Syneos Health and WuXi AppTec.

Key Questions Answered in This Report

• 1. What was the size of the global in-vivo CRO market in 2023?
• 2. What is the expected growth rate of the global in-vivo CRO market during 2024-2032?
• 3. What are the key factors driving the global in-vivo CRO market?
• 4. What has been the impact of COVID-19 on the global in-vivo CRO market?
• 5. What is the breakup of the global in-vivo CRO market based on the type?
• 6. What is the breakup of the global in-vivo CRO market based on the GLP type?
• 7. What is the breakup of the global in-vivo CRO market based on indication?
• 8. What are the key regions in the global in-vivo CRO market?
• 9. Who are the key players/companies in the global in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global In-vivo CRO Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Rodent
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Rats
    • 6.1.2.2 Mice
    • 6.1.2.3 Others
  • 6.1.3 Market Forecast
• 6.2 Non-Rodent
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by GLP Type

• 7.1 Non-GLP
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 In House
    • 7.1.2.2 Outsourcing
  • 7.1.3 Market Forecast
• 7.2 GLP Toxicology
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 In House
    • 7.2.2.2 Outsourcing
  • 7.2.3 Market Forecast

8 Market Breakup by Indication

• 8.1 Autoimmune/Inflammation Conditions
  • 8.1.1 Market Trends
  • 8.1.2 Key Segments
    • 8.1.2.1 Rheumatoid Arthritis
    • 8.1.2.2 Multiple Sclerosis
    • 8.1.2.3 Osteoarthritis
    • 8.1.2.4 Irritable Bowel Syndrome
    • 8.1.2.5 Others
  • 8.1.3 Market Forecast
• 8.2 Pain Management
  • 8.2.1 Market Trends
  • 8.2.2 Key Segments
    • 8.2.2.1 Chronic Pain
    • 8.2.2.2 Acute Pain
  • 8.2.3 Market Forecast
• 8.3 Oncology
  • 8.3.1 Market Trends
  • 8.3.2 Key Segments
    • 8.3.2.1 Blood Cancer
    • 8.3.2.2 Solid Tumor
    • 8.3.2.3 Others
  • 8.3.3 Market Forecast
• 8.4 CNS Conditions
  • 8.4.1 Market Trends
  • 8.4.2 Key Segments
    • 8.4.2.1 Epilepsy
    • 8.4.2.2 Parkinson's Disease
    • 8.4.2.3 Huntington's Disease
    • 8.4.2.4 Stroke
    • 8.4.2.5 Traumatic Brain Injury
    • 8.4.2.6 ALS
    • 8.4.2.7 Muscle Regeneration
    • 8.4.2.8 Others
  • 8.4.3 Market Forecast
• 8.5 Diabetes
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Obesity
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Charles River Laboratories International Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Evotec SE
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 ICON plc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Iris Pharma (ABIONYX Pharma)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Labcorp Drug Development (Laboratory Corporation of America Holdings)
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 SWOT Analysis
  • 14.3.6 North American Science Associates LLC
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Parexel International Corporation
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Pronexus Analytical AB
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Syneos Health
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 WuXi AppTec
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials